chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I have had significant daily heart palpitations and spasms in a specific area in my right/ middle section of chest. This occur on a daily basis and began a few months after second shot. They are occurring 50 plus times a day. I had to go to cardiologist and had to wear a heart holter this week and am awaiting results. Additionally I am experiencing dizziness upon standing or sitting for unexplained reasons . My Mother  had the same vaccine the week prior and has had the exact same issues. I had rye heart issue on same side as injection site and I also had a rash on leg on same side which went away and then came back a month later.
Developed Guillain Barre syndrome 5 days after receiving dose #1 of Shingrix
I took my nightly statin pill about 6 hours after receiving my 1st vaccination shot and went to bed.  About 4 hours later, I woke from a sound sleep with the most painful cramps in both lower legs that I've ever experienced.  Both feet were flexing upwards and my lower calf muscles taught uncontrollably.  I managed to get out of bed and onto my feet to put my weight on them; but had to balance on a nearby chair.  Only after an intensely painful 45 minutes did the muscles begin to relax!! (When first prescribed statins 10 years ago, I found they particularly could cause a cramp in one of my legs at night.  Only after trying several varieties of statins and lower doses did I find one --the generic Pravastatin-- and dose that would not trigger this nighttime cramping.  In further defense, I also try to stay hydrated and drink a glass of water before going to bed each night.) *NOTE: In order to avoid that incredible pain, I DO NOT plan to take my statin pill the night when I get my 2nd dose!!
8 days after 2nd dose of vax pt suffered massive visual disturbances which devel into total loss of sight;  Annual follow up received on 11/27/00 provided no additional information.
COVID 19; COVID 19; This is a spontaneous report received from a contactable reporter(s) (Nurse). The reporter is the patient.  A 46-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 01Sep2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 45 years, in right arm for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "hashimotos" (unspecified if ongoing); "Multiple sclerosis" (unspecified if ongoing). Concomitant medication(s) included: TECFIDERA, start date: 01Dec2015. Past drug history included: Gabapentin, reaction(s): "Drug Allergy", notes: Gabapentin causes hives; Gabapentin, reaction(s): "hives". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19". Therapeutic measures were taken as a result of drug ineffective, covid-19. The patient took Paxlovid (treatment start date: 18Sep2023, treatment stop date: 22Sep2023).  The information on the batch/lot number for bnt162b2, bnt162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Based on available information, a lack of efficacy with the suspect vaccine bnt162b2, bnt162b2 omi ba.4-5 in this patient cannot be completely excluded.
First dose of Shingrix vaccine on 2/24/20 / Not received the second dose yet; Rash on legs/ from knee down to ankle; This case was reported by a consumer via call center representative and described the occurrence of rash in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 24th February 2020, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, the patient received the 2nd dose of Shingrix. On 25th February 2020, 1 days after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced rash. On an unknown date, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the rash was recovered/resolved and the outcome of the incomplete course of vaccination was unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were provided as follows: The patient received 1st dose of Shingrix in left arm and the day after receiving Shingrix, the patient experienced rash on front of both of legs from knee down to ankle. The rash lated for 3 days and then resolved. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter did not consent to follow up.
VACCINATION SITE BECAME RED, HARD AND HOT TO THE TOUCH THE DAY AFTER BEING IMMUNIZED
About 45 seconds after administration of Gardasil (dose #3) to upper right deltoid, client showed circumoral and circumnasal pallor, slurred speech and her eyes rolled back and closed as she lost consciousness.  She was lowered safely to prone position, cool compress applied to forehead and feet elevated.  After about a minute of calling her name and gently tapping her she started to come around.  After a few minutes she was able to sit with support and sipped some cool water.  Within 5-7 minutes she was able to stand with assistance and left about 10 minutes later with her family, walking on her own though still a bit pale.  Parents reported she had not had lunch yet.
Severe fatigue, debilitating headache, rash. severe face swelling, soreness at injection site, extremely high CRP (96.5) blood test symptoms came slowly over 3 days - 4 dr. visits.
seen in ER for episode of lifelessness;went suddenly pale & limp w/slow breathing;responsive to name only lasted 30-45min w/return of color & activity suddenly while in ER;associated w/T101 & no obvious source on exam;
Patient complained of a sore arm after the vaccination. Now two days later patient states that arm is now red and swollen and is still sore.
Information has been received from a physician concerning an 11-year-old female with no pertinent medical history who on 23-JUL-1996 was vaccinated with her first dose of Varivax. There was no concomitant medication. On 12-DEC-2006, it was noted that the patient's mother had shingles and it was unknown if the mother had been vaccinated with Varivax. On 26-DEC-2006, 14 days after the mother had shingles, the patient experienced "breakthrough," with an unspecified number of lesions. Unspecified medical attention was sought. The patient was "fine" at the time of this report. No additional information was available. There was no product quality complaint involved. Additional information has been requested.
Tightening of neck, light headed- symptoms remained the same during monitoring.  Did not get better of worse.  Patient stated she took tylenol before vaccine and will take ibuprofen when she gets home.  Water given.
Pt vaxed w/MMR 12JAN90 due to measles epidemic; Next day devel muscle aches & rash which became generalized by 16JAN90; unsuccessfully treated w/DPH, then treated w/Pred; @ end of Pred therapy hives reappeared;
Inflammation of lymph node on right side of neck causing extreme pain, duration 10 days.  Severe headache, duration 10 days.  Fatigue, duration 5 days.
has experienced muscular aches; This is a spontaneous report received from contactable reporter(s) (Physician) from a representative.  A female patient in her 50's received BNT162b2 (COMIRNATY), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE; MANUFACTURER UNKNOWN), for Covid-19 immunization; Covid-19 vaccine (DOSE 2, SINGLE; MANUFACTURER UNKNOWN), for Covid-19 immunization. The following information was reported: MYALGIA (non-serious), outcome "unknown", described as "has experienced muscular aches".  Additional information: After first 3 doses of vaccine, has experienced muscular aches. Decided not to be vaccinated with 4th and bivalent vaccines.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Pain at the injection site (right arm); This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP).  A 19 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 31Mar2021 (Lot number: EP6955) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 31Mar2021 22:00, outcome "recovered" (02Apr2021 09:00), described as "Pain at the injection site (right arm)".  Additional information: Intensity: Mild. Reporter mentioned that patient woke up on 02Apr21 and the pain was gone.  No follow-up attempts are needed. No further information is expected.
patient had sore shoulders for a few days after the vaccine. woke up 3/3/2021 with left shoulder pain and unable to lift left arm. left arm was the vaccine site. concern for SIRVA.
6x6 red, swollen, warm to touch area right deltoid. F/u 11/02/06, apply ice take Ibuprofen 600mg TID.
Dizziness; Trouble breathing; Rapid heart beat; Issues with stomach; A spontaneous report  was received from a consumer concerning a 72-year old male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and developed rapid heartbeat (palpitations), dizziness, trouble breathing (dyspnoea) and issues with stomach (abdominal discomfort).  The patient's medical history was not provided. Concomitant medications were not provided.  On 18 Feb 2021, the patient received their first of the two planned doses of mRNA-1273 (Batch number: unknown) in the left arm for the prophylaxis of COVID-19 infection.  On 18 Mar 2021, the patient received their second of the two planned doses of mRNA-1273 (Batch number: unknown) for the prophylaxis of COVID-19 infection.  On 21 Mar 2021, patient experienced a rapid heartbeat, dizziness, trouble breathing, issues with stomach. Patient was hospitalized at Memorial Hospital where he was kept overnight. No discharge date provided.  The events rapid heartbeat, dizziness, trouble breathing and issues with stomach resulted in hospitalization.   Treatment information was not provided. Lab tests not provided.  The patient received both scheduled doses of mRNA-1273 prior to the events, therefore action taken with the drug in response to the events was not applicable.  The outcome of the events, rapid heartbeat, dizziness, trouble breathing and issues with stomach was considered unknown. .; Reporter's Comments: Very limited information regarding these events has been provided at this time. Further information has been requested.
I got my flu shot on Friday.On Saturday am I was at work and started to fell very dizzy and off balance. My vision started to become little blurry and I started to see double. It concerned me a lot, I never had those symptoms before. I was not able to focus, felt spaced out and decided to go home to rest. Slept for couple hours and was fine next day.
lethargic, extremely tired, nausea, heart going out of rhythm, shortness of breath for 6 days now
Shortly after receiving  first dose of Moderna vaccine patient experienced localized arm redness where shot had been administered.   Patient remained at pharmacy for 30 min for observation.  Redness did not get worse and patient was not experiencing any other symptoms that shes believed to be related to vaccine.  Instructed patient to call MD if redness/rash worsened.
tested positive for covid-19; tested positive for covid-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 08Sep2022 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary immunization series complete; Manufacture unknown), for covid-19 immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 17Sep2022, outcome "not recovered" and all described as "tested positive for covid-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (15Sep2022) Negative; (16Sep2022) Negative; (17Sep2022) Positive. Clinical course: On 08Sep2022, the patient got the updated Covid vaccine. On 14Sep2022 was the beginning of some symptoms. At that day it was like just little cough seems like an allergic cough but by 15Sep2022 morning, it was obvious that something was going on. So, the patient tested negative on 15Sep2022, tested negative on 16Sep2022, tested positive on the 17Sep2022. Seriousness reported as no.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
presented to vaccine clinic - received vaccination and while waiting - observer noted person was swallowing  frequently and asked if she was doing okay - she stated she felt a pressure in her chest "like my asthma" - relayed she thought she needed some Benadryl.  Person was masked - observing staff asked for her to remove her mask and they noted where her mask was a pink to red outline of a fine rash.  Person was subsequently taken to the ED for further evaluation and any needed treatment.    ED notations:  Patient is a pleasant 57 year old female  with a history of asthma, eczema, obesity, LE edema presenting for vaccine reaction. Patient states she was upstairs at SCB getting her first COVID shot. She was sitting in the waiting area after receiving injection and noted to have sensation of chest tightness "similar to my asthma" within 10 minutes of receiving the vaccine. She was noted by nursing staff to also have redness to her face. Patient denied any difficulty breathing or swallowing, no raised rash/bumps to her face or body, no palpitations or fast heart rate, no swelling more than her usual baseline LE edema. She denies headache, feeling light headed, nauseous, or any symptoms of abdominal discomfort. Patient has a history of allergies to sulfa drugs and seasonal allergies, no food allergies/intolerances, or previous reactions to vaccines. Patient was determined to not be in anaphylactic shock but did have immediate symptoms after injection suggesting an allergic Type I hypersensitivity, redness and sensation in her chest improved with 50 mg of benadryl.  The patient was reassured after an observational period of about 1 hour and no additional symptoms. She was notified that CDC guidelines are that even with a mild allergic reaction to the vaccine, that she should avoid getting the 2nd in series, continuing to practice other preventative measures against COVID, maintaining social distance and wearing a mask.
Information has been received from a nurse practitioner concerning a 14 year old female who was vaccinated with a second dose of Gardasil. Subsequently "about a day or two" after receiving the vaccination the patient developed rash all over her body. The patient returned to the office and they confirmed the rash was everywhere. A Streptococcus oralis culture came back negative. The patient was advised to take diphenhydramine 10/08/07 This is in follow-up to report(s) previously submitted on 7/16/2007. Initial and follow-up information has been received from a nurse practitioner concerning a 17 year old female (previously reported as 14 years), with no pertinent medical history, who on 14-MAY-2007 was vaccinated IM in the left deltoid with a second dose of GARDASIL (lot # 655205/1426F). On 18-MAY-2007 at 10:00 am, the patient developed a rash covering her torso (previously reported as all over her body). The patient returned to the office and they confirmed the rash "it was everywhere". A Strepococcus oralis culture came back negative. The patient was advised to take BENADRYL. Subsequently, the patient recovered from the rash on her torso. Additional information is not expected.
NOTHING LOCALLY AT TIME OF IMMUNIZATION. NO PROBLEM 15-30MINUTES LATER. WAS INFORMED SHE WAS FOUND DEAD THE NEXT MORNING.
Rash all over my chest and Shoulders; This is a spontaneous report from a contactable consumer. A 61-year-old non-pregnant female patient received bnt162b2 (BNT162B2, solution for injection, Lot Number: EN6206), via an unspecified route of administration, administered in Arm Left on 06Mar2021 09:15 (at the age of 61-year-old) as dose number unknown, single for COVID-19 immunisation. Medical history included none. Concomitant medication(s) included lisinopril. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no allergies to medications, food, or other products. The patient had no other medical history. Since the vaccination, the patient has not been tested for COVID-19. The patient experienced rash all over my chest and shoulders on 07Mar2021 with outcome of not recovered.  No follow-up attempts are possible. No further information is expected.
Clinic Nurse misread screening form DOB and did not verify ID. Patient was given vaccination under 18yo which is contraindicated by Moderna at this time.
Tingling tongue, knot felt under jaw/neck near lymph node on right side (vaccine administered into left deltoid 1.5 hours prior.  TMJ sore and tender, right side of face tingly and numb.  No problems with speaking, drinking, etc.  No changes in vision, speech, hearing.  Symptoms only in facial area on Right side.  Arms and legs with normal sensation.  No chest pain or shortness of breath.  By 6pm that day, all symptoms were resolved and have not recurred.
Child received immunizations and about 12 hours later, developed a non-itchy rash all over his body except on back. No temperature. Rash began fading, 24 hours, post vax.
Hot injection site; Itchy injection site; Site of injection started swelling; Pain at injection site; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION SITE WARMTH (Hot injection site), VACCINATION SITE PRURITUS (Itchy injection site), VACCINATION SITE SWELLING (Site of injection started swelling) and VACCINATION SITE PAIN (Pain at injection site) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jan-2021, the patient experienced VACCINATION SITE WARMTH (Hot injection site), VACCINATION SITE PRURITUS (Itchy injection site), VACCINATION SITE SWELLING (Site of injection started swelling) and VACCINATION SITE PAIN (Pain at injection site). At the time of the report, VACCINATION SITE WARMTH (Hot injection site), VACCINATION SITE PRURITUS (Itchy injection site) and VACCINATION SITE SWELLING (Site of injection started swelling) outcome was unknown and VACCINATION SITE PAIN (Pain at injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. Advil was reported as treatment medication.
Painful R arm; shoulder pain following the injection; Foggy feeling in head; Headache; This spontaneous case was reported by a physician and describes the occurrence of FEELING ABNORMAL (Foggy feeling in head), PAIN IN EXTREMITY (Painful R arm), HEADACHE (Headache) and ARTHRALGIA (shoulder pain following the injection) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 007M20A and 024M20A) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    The patient's past medical history included Occlusion coronary artery from September 2020 to December 2020, Pneumonia from 19-Oct-2020 to 31-Oct-2020, Limb injury in July 2020, Broken nose in July 2020, Bursitis worsened, Loss of posture in July 2020, Automobile accident, Back pain (with radiation) in May 2019, Leg pain in May 2019, Alcohol use (6 cans of beer or less than 8 ounce occasionally.) in 1955 and Tobacco user (Half to one pack of cigarettes per day.) in 1999. Concurrent medical conditions included Heart disorder since August 2020, Osteoarthritis since September 2020, Spinal osteoarthritis, Aching joints in March 2020, Pain, Iron deficiency since October 2020, Heart rate irregular, Swelling of hands in December 2019, Bronchiectasis in 2019, Type 2 diabetes mellitus, Asthma and Pollen allergy (Tightness with the bronchioles when breathing.). Concomitant products included OMEPRAZOLE for Acid reflux (esophageal), MONTELUKAST for Allergy NOS and Asthma, ASPIRIN [ACETYLSALICYLIC ACID] and ROSUVASTATIN for Anticoagulant therapy, METFORMIN for Glucose, GABAPENTIN for Joint pain, MAGNESIUM for Magnesium supplementation, LEFLUNOMIDE for Rheumatoid arthritis, GLUCOSAMINE for Supplementation therapy, VITAMIN B COMPLEX for Vitamin B complex supplementation, CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]) for Vitamin B12 supplementation, VITAMIN D3 for Vitamin D supplementation.   In October 2018, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 mg every two weeks. On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In February 2021, the patient experienced HEADACHE (Headache). On 21-Feb-2021, the patient experienced FEELING ABNORMAL (Foggy feeling in head). On an unknown date, the patient experienced PAIN IN EXTREMITY (Painful R arm) and ARTHRALGIA (shoulder pain following the injection). At the time of the report, FEELING ABNORMAL (Foggy feeling in head), PAIN IN EXTREMITY (Painful R arm), HEADACHE (Headache) and ARTHRALGIA (shoulder pain following the injection) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.
5 MINUTES AFTER RECEIVING MODERNA (2ND DOSE) PATIENT BEGAN TO FEEL DIZZY.  AFTER BEING PLACED ON THE FLOOR WITH A BLANKET AND PILLOW HE BEGAN TO COMPLAIN OF CHEST PAIN AND WAS COLD.  911 WAS CALLED.  PARAMETICS ARRIVED, THEY CHECKED HIS BLOOD PRESSURE WHICH WAS NORMAL. THEY INQUIRED IF HE HAD A REACTION BEFORE AND HE SAID NO. THEY ASKED IF HE HAD MEDICAL CONDITIONS AND HE SAID DIABETIC. THEY ASKED IF HE HAD EATEN AND HE SAID HE HAD BREAKFAST. THEY THEN PUT HIM ON THE STRETCHER AND TOOK HIM TO THE HOSPITAL.
Became sick afterwards; Local paediatrician sent me at the first vial so i tested and turned out to be positive altogether 16 vial; This spontaneous report was received from a consumer via social media refers to a patient of unknown age. On an unknown date, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) or quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) for prophylaxis. On an unknown date, the patient received the "faux" placebo of HPV vaccine and became sick (malaise) afterwards. There was no saline placebo it was a faux placebo. The physician reported in social media regarding product quality complain "Local paediatrician sent me at the first vial so reporter tested and turned out to be positive (altogether 16 vial) (product quality issue)". The outcome of malaise and product quality issue was unknown. Reporter's causality was not provided.